Samik Pharmaceutical Co., Ltd. Surges 18% on Patent for Once-Monthly Immunomodulator Administration [Stock NOW]

[Financial News] Samik Pharmaceutical Co., Ltd. is surging in early trading following news of the domestic patent registration for a long-acting formulation technology that allows the immunomodulatory peptide 'Thymosin Alpha-1' to be administered at a once-monthly level. As of 10:09 AM on the 14th, Samik Pharmaceutical Co., Ltd. is trading at 9,330 won on the KOSDAQ (Korea Securities Dealers Automated Quotations) market, up 1,420 won (17.95%) from the previous trading day. The stock reached 9,340 won during the session, setting a new 52-week high. Trading volume has also exceeded 14.16 million shares, appearing significantly higher than usual.
This week's rise in stock price is interpreted as reflecting expectations regarding the patent for 'long-acting microspheres containing Thymosin Alpha-1, a composition containing the same, and a method for manufacturing the same,' which Samik Pharmaceutical Co., Ltd. registered on the 27th of last month.
The key point is that the company has secured formulation technology capable of significantly reducing the frequency of administration of Thymosin Alpha-1, which previously required repeated administration.
Thymosin Alpha-1 is a peptide that activates T cells to regulate immune responses. However, due to its characteristics of being highly soluble in water and rapidly degrading in the body, existing aqueous formulations are known to require subcutaneous injections at least twice a week to maintain efficacy.
Samik Pharmaceutical Co., Ltd. plans to apply this patent not only to Thymosin Alpha-1 but also to the development of long-acting formulations of other peptide drugs that are rapidly broken down in the body and require repeated administration.
Meanwhile, this patent registration does not mean the immediate launch of a commercial product or the confirmation of clinical efficacy for a once-monthly product. Investors must also consider that subsequent development, clinical trials, and regulatory approval procedures are required for actual commercialization.

[email protected] Kang Jung-mo Reporter